Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Oesophageal and gastric cancers

ASCO Direct Highlights™ Miami 2021 Symposium

9 - 10 Jul 2021

Published: 28 Jul 2021

Views: 720

Rating:

Save

Dr Mike Cusnir - Mount Sinai Medical Center, Florida, USA

Dr Mike Cusnir speaks to ecancer about the updates from ASCO 2021 related to oesophageal and gastric cancers.

He discusses some of the data regarding these cancers and how they can impact the future treatment of oesophageal and gastric cancer.

Watch the meeting in full by following the links below:

Related Videos

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Immunotherapy significantly increases the number of patients free from bowel...

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh...

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

More from ecancer